2. Section 275.203A–6 is added to read as follows:

§ 275.203A–6 Transition period for Ohio investment advisers.

(a) *Ohio Authority.* Notwithstanding section 203A(b) of the Act (15 U.S.C. 80b–3a(b)), the Ohio Revised Code, sections 1707.01 to 1707.99, is effective with respect to an investment adviser registered with the Commission that, but for having its principal office and place of business in Ohio, would be prohibited from registering with the Commission under section 203A of the Act (15 U.S.C. 80b–3a).

(b) *Withdrawal Required.* Every investment adviser that is registered with the Commission solely because its principal office and place of business is located in Ohio must withdraw from Commission registration by March 30, 2000.

PART 279—FORMS PRESCRIBED UNDER THE INVESTMENT ADVISERS ACT OF 1940

3. The authority citation for part 279 continues to read as follows:

Authority: The Investment Advisers Act of 1940, 15 U.S.C. 80b–1, *et seq.*

4. By amending Schedule I to Form ADV (referenced in § 279.1) to remove all references to ''Ohio'' and by amending the Instructions to Schedule I to Form ADV (referenced in § 279.1) to remove all references to ''Ohio''.

§ 279.1 [Amended]

Note: The text of Schedule I to Form ADV (§ 279.1) does not and the amendments will not appear in the Code of Federal Regulations.

Dated: March 25, 1999.

By the Commission.

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 99–7955 Filed 3–31–99; 8:45 am]

BILLING CODE 8010–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, 522, and 558

Animal Drugs, Feeds, and Related Products; Technical Amendments

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is updating the animal drug regulations to reflect corrections of previously approved new animal drug applications (NADA's). Several sponsors currently specified in the list of sponsors of approved applications and in the animal drug approval regulations are incorrect. This action is being taken to improve the accuracy of the regulations.

EFFECTIVE DATE: April 1, 1999.

FOR FURTHER INFORMATION CONTACT: Judith M. O'Haro, Center for Veterinary Medicine (HFV–6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–3664.

SUPPLEMENTARY INFORMATION: FDA has found several errors in the agency's regulations concerning approval of animal drugs, feeds, and related products including the list of sponsors of approved applications. To correct those errors, FDA is amending 21 CFR 510.600(c)(1) and (c)(2) to remove several sponsor names and drug labeler codes because the firms are no longer the holders of any approved NADA's. This document is also amending the animal drug approval regulations by correcting the nonsubstantive errors in 21 CFR 520.260, 520.2184, 520.2220b, 522.723, 522.800, 558.140, 558.485, and 558.635.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Parts 520 and 522

Animal drugs.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in the table in paragraph (c)(1) by removing the entries for ''Affiliated Laboratories Division, Whitmoyer Laboratories, Inc.'', ''Albers Milling Co.'', ''Allied Pharmacal, Division of K.C. Pharmacal, Inc.'', ''Ayerst Laboratories, Division of American Home Products, Corp.'', ''Bristol Laboratories, Div. of Bristol-Myers Co.'', ''Cooper U.S.A., Inc.'', ''Cutter Laboratories, Inc.'', ''Dawes Laboratories, Inc.'', ''Feed Products, Inc.'', ''H. Clay Glover Co., Inc.'', ''Gooch Feed Mill Corp.'', ''Grain Processing Corp.'', ''ICI Americas, Inc.'', ''KASCO–EFCO Laboratories, Inc.'', ''Dr. LeGear, Inc.'', ''McNeil Laboratories, Inc.'', ''Triple ''F'', Inc.'', ''Tutag Pharmaceuticals, Inc.'', and ''Western Serum Co.''; by alphabetically adding a new entry for ''Equi Aid Products, Inc.''; and in the table in paragraph (c)(2) by removing the entries for ''000015, 000045, 000046, 000124, 000161, 000794, 010471, 010616, 011398, 011490, 011492, 011511, 011825, 011950, 012983, 013959, 017826, 021798, 022591, and 024264''; and by numerically adding a new entry for ''062240'' to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

* * * * *

(c) * * *

(1) * * *

Firm name and address	Drug labeler code
* * * *	* * *
Equi Aid Products, Inc., 1517 West Knudsen Dr., Phoenix, AZ 85027	062240
* * * *	* * *

(2) * * *

Drug labeler code	Firm name and address
* * * *	* * *
062240	Equi Aid Products, Inc., 1517 West Knudsen Dr., Phoenix, AZ 85027
* * * *	* * *

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

3. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 520.260 [Amended]

4. Section 520.260 *n-Butyl chloride capsules* is amended in paragraph (b)(2) by removing ''012983'' and adding in its place ''038782''.

§ 520.2184 [Amended]

5. Section 520.2184 *Sodium sulfachloropyrazine monohydrate* is amended in paragraph (b) by removing the phrase ''Nos. 010042 and 053501'' and adding in its place ''No. 010042''.

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

6–7. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

§ 522.723 [Amended]

8. Section 522.723 *Diprenorphine hydrochloride injection* is amended in pargraph (c) by removing ''010042'' and adding in its place ''053923''.

§ 522.800 [Amended]

9. Section 522.800 *Droperidol and fentanyl citrate injection* is amended in pargraph (b) by removing ''000045'' and adding in its place ''000061''.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

10. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

§ 558.140 [Amended]

11. Section 558.140 *Chlortetracycline and sulfamethazine* is amended in paragraph (a) by removing ''000004'' and adding in its place ''063238''.

§ 558.485 [Amended]

12. Section 558.485 *Pyrantel tartrate* is amended by removing and reserving paragraph (a)(17).

§ 558.635 [Amended]

13. Section 558.635 *Virginiamycin* is amended in paragraph (b)(2) by removing ''011490'' and adding in its place ''046573''.

Dated: March 23, 1999.

Margaret Ann Miller,

Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 99–7925 Filed 3–31–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Sulfadimethoxine Tablets and Boluses; Technical Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to codify an approved new animal drug application (NADA) held by Pfizer, Inc. The NADA provides for use of sulfadimethoxine (SDM) tablets to treat bacterial infections of dogs and cats.

EFFECTIVE DATE: April 1, 1999.

FOR FURTHER INFORMATION CONTACT: Diane T. McRae, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0212.

SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 East 42d St., New York, NY 10017, is sponsor of NADA 15–102 that provides for oral use of SDM tablets for the treatment of SDM-susceptible bacterial infections of dogs and cats. The NADA was approved on December 14, 1964, for Hoffmann LaRoche, Inc. After several changes of sponsors, the current sponsor of the NADA, Pfizer, Inc., has filed a supplement to NADA 15–102 providing information supporting prior approval of their NADA and has requested codification. FDA concurs that NADA 15–102 was approved for use in dogs and cats on December 14, 1964, and therefore, amends 21 CFR 520.2220b to reflect the approval. Also, FDA is amending the regulation to add several editorial changes by removing paragraph (a), by redesignating paragraphs (b), (d), and (e) as paragraphs (a), (b), and (d), respectively, and by revising new paragraphs (a) and (d)(2) to reflect the codification.

Approval of this supplemental NADA does not require additional safety and effectiveness data. Therefore, a freedom of information summary is not required.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subject 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

2. Section 520.2220b is amended by removing paragraph (a), by redesignating paragraphs (b), (d), and (e) as paragraphs (a), (b), and (d), respectively, and by revising newly redesignated paragraphs (a) and (d)(2) to read as follows:

§ 520.2220b Sulfadimethoxine tablets and boluses.

(a) *Sponsors.* Approval to firms identified in § 510.600(c) of this chapter as follows:

(1) To 000069, approval for use as in paragraphs (d)(1), (d)(2), and (d)(3) of this section.